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Abstract: Focused ultrasound (FUS) coupled with microbubbles (MB) has been found to be a 
promising approach to disrupt the blood-brain barrier (BBB). However, how this disruption affects 
drug transport remains unclear. In this study, drug transport in combination therapy of liposomes 
and FUS-MB-induced BBB disruption (BBBD) was investigated based on a multiphysics model. A 
realistic 3D brain tumour model extracted from MR images was applied. The results demonstrated 
the advantage of liposomes compared to free doxorubicin injection in further improving treatment 
when the BBB is opened under the same delivery conditions using burst sonication. This 
improvement was mainly due to the BBBD-enhanced transvascular transport of free doxorubicin 
and the sustainable supply of the drug by long-circulating liposomes. Treatment efficacy can be 
improved in different ways. Disrupting the BBB simultaneously with liposome bolus injection 
enables more free drug molecules to cross the vessel wall, while prolonging the BBBD duration 
could accelerate liposome transvascular transport for more effective drug release. However, the 
drug release rate needs to be well controlled to balance the trade-off among drug release, 
transvascular exchange and elimination. The results obtained in this study could provide 
suggestions for the future optimisation of this FUS-MB–liposome combination therapy against brain 
cancer. 
Keywords: blood-brain barrier disruption; brain tumour; drug transport; focused ultrasound; 
liposome-mediated delivery; mathematical model 
 
1. Introduction 
Malignant glioma is highly invasive and aggressive, with a high mortality rate and short 
survival time [1]. Although a number of drugs have been developed with outstanding anticancer 
effectiveness shown in preclinical trials, their clinical performance for treating brain tumours remains 
disappointing. This could be attributed to the blood-brain barrier (BBB) [2], which is able to prevent 
over 98% of drugs from crossing the blood vessel wall in routine chemotherapy [3]. 
Focused ultrasound (FUS) coupled with systemically injected microbubbles (MB) has been 
found to be a promising approach by which to open the BBB [4]. Despite recovering gradually after 
the sonication ends [5], the temporary blood–brain barrier disruption (BBBD) can successfully enable 
intravenously administrated drugs to enter brain tumours for cell killing. This enhanced 
transvascular transport could be more significant for drugs like doxorubicin, to which the BBB is 
normally nearly impermeable [6,7]. Given that its clinical use is highly limited by serious adverse 
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effects, especially cardiotoxicity, doxorubicin in a liposome-encapsulated form has been approved by 
the FDA as an alternative [8]. However, it is not clear how BBBD influences drug transport in 
liposome-mediated delivery, which can largely determine delivery outcomes and treatment efficacy. 
Numerical simulation has become an effective way to study chemotherapy [9]. It has the 
advantage of being able to incorporate realistic tumour and drug properties to mimic multiple drug-
delivery processes, which are difficult to observe directly in in vivo experiments. An initial 
mathematical model was set up to examine the roles of different intra-tumoural environments on the 
delivery of antibodies [10–12]. In subsequent developments, mathematical descriptions of more 
realistic and complex processes were incorporated to tailor the model to different delivery systems 
and strategies [13–16]. The delivery of doxorubicin under various delivery conditions has been 
studied extensively by means of numerical simulation [17–20], while the performance of free 
doxorubicin in combination with FUS-induced BBBD has been evaluated based on an idealised 
tumour model in 2D [21]. However, there is still a lack of modelling studies on liposome-mediated 
delivery coupled with FUS-MB-induced BBBD. 
This simulation study aimed to examine the effects of FUS-MB-induced BBBD on drug transport 
in liposome-mediated drug delivery. A realistic 3D geometrical model of a brain tumour and its 
surrounding tissue was reconstructed from magnetic resonance (MR) images. The multiphysics 
model adopted incorporated key delivery processes including FUS- and MB-induced BBBD and its 
recovery; drug exchange among blood, tumour and normal tissues; drug convective and diffusive 
transport in the interstitial fluid flow; release from liposomes; drug physical degradation and 
metabolic reactions; binding with proteins and cell uptake; etc. The delivery outcomes, including the 
cytotoxicity to tumour cells and the risk of cardiotoxicity, were evaluated in terms of drug exposure 
over time in the brain tumour and blood circulatory system, respectively. 
2. Materials and Methods 
2.1. Mathematical Model 
This mathematical model consisted of several submodules in order to describe the interlinked 
physiological and physicochemical processes involved in the drug delivery. These included the 
interstitial fluid flow across the entire brain and transport of liposomal and/or free drug among the 
blood circulatory system and different tissue compartments. 
2.1.1. Interstitial Fluid Flow 
Microvasculature in solid tumours is elongated, dilated and tortuous, and its morphological 
characteristics can vary considerably with the tumour’s specific type and growth stage [22]. The 
distance between capillaries is around 33–98 μm, which is 2–3-fold lower than the dimension of both 
the tumour and its surrounding tissues [12]. Hence, a brain tumour and its surrounding tissue can be 
treated as porous media, where the Navier–Stokes equation is applicable to describe the 
incompressible, Newtonian interstitial fluid flow. The function of microvasculature can then be 
considered a source term in the mass equation [11], as follows. 
∇ ∙ 𝐯𝐯 = 𝐹𝐹𝑏𝑏 (1) 
∇(𝜌𝜌𝐯𝐯𝐯𝐯) = −𝛻𝛻𝑝𝑝𝑖𝑖 + 𝜇𝜇∇2𝐯𝐯 − �𝜇𝜇𝜅𝜅� 𝐯𝐯 (2) 
where the velocity and pressure of interstitial fluid flow are represented by v and pi, respectively. ρ 
and μ denote the density and viscosity of interstitial fluid, respectively, and κ is the tissue’s Darcian 
permeability. Starling’s law is used to calibrate the flux of fluid loss from blood (Fb). 
𝐹𝐹𝑏𝑏 = 𝐾𝐾𝑏𝑏 𝑆𝑆𝑉𝑉 [𝑝𝑝𝑏𝑏 − 𝑝𝑝𝑖𝑖 − 𝜎𝜎𝑇𝑇(𝜋𝜋𝑏𝑏 − 𝜋𝜋𝑖𝑖)] (3) 
where pb is the blood pressure and Kb is the hydraulic conductivity of the blood vessel wall. The 
vascular density is represented by S/V, which is defined as the area of blood vessel wall in the total 
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tissue volume. σT is the averaged osmotic reflection coefficient for proteins in blood. πb and πi are the 
osmotic pressures of blood and interstitial fluid, respectively. 
2.1.2. Direct Delivery of Free Doxorubicin 
Figure 1 shows the transport processes of non-encapsulated doxorubicin delivered via bolus 
injection. The doxorubicin concentration (𝐶𝐶) in the intravascular space (IVS) can be described by 
𝐶𝐶𝐼𝐼𝐼𝐼𝐼𝐼 = 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝑉𝑉𝐹𝐹,𝑑𝑑 𝐷𝐷−𝑘𝑘𝐹𝐹,𝑐𝑐𝑡𝑡 (4) 
where 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 represents the total amount of the drug used in the treatment, and 𝑡𝑡 is time. 𝑉𝑉𝐹𝐹,𝑑𝑑 stands 
for the drug distribution volume, and 𝑘𝑘𝐹𝐹,𝑐𝑐 is its plasma clearance rate. Free doxorubicin is able to 
associate and dissociate with proteins in a dynamic manner towards equilibrium [20]. Therefore, the 
intravascular concentration of free doxorubicin (𝐶𝐶𝐹𝐹,𝐼𝐼𝐼𝐼𝐼𝐼) can be calibrated by the mass conservation 
equation as follows. 
 
Figure 1. Transport processes involved in direct drug delivery in combination with focused-
ultrasound-and-microbubble (FUS-MB)-induced blood–brain barrier disruption (BBBD). Red dashed 
line indicates the disrupted BBB, and the enhanced transvascular transport processes are highlighted 
in green. 
𝐶𝐶𝐼𝐼𝐼𝐼𝐼𝐼 = 𝐶𝐶𝐹𝐹,𝐼𝐼𝐼𝐼𝐼𝐼 + 𝐶𝐶𝐵𝐵,𝐼𝐼𝐼𝐼𝐼𝐼 = 𝐶𝐶𝐹𝐹,𝐼𝐼𝐼𝐼𝐼𝐼(1 + 𝐾𝐾𝐼𝐼𝐼𝐼𝐼𝐼) (5) 
where 𝐶𝐶𝐵𝐵,𝐼𝐼𝐼𝐼𝐼𝐼 denotes the concentration of bound doxorubicin in blood and 𝐾𝐾𝐼𝐼𝐼𝐼𝐼𝐼 is the constant of 
drug binding with proteins. 
Both the brain tumour and its surrounding tissue can be briefly divided into the intracellular 
space (ICS), cell membrane (CM), and extracellular space (ECS). Governed by the mass conservation 
equation, the free doxorubicin concentration in the entire tissue (CF) can be expressed in the form of 
[16,23] 
𝜕𝜕𝐶𝐶𝐹𝐹
𝜕𝜕𝑡𝑡
= 𝜐𝜐𝐸𝐸𝐸𝐸𝐼𝐼𝐷𝐷𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼∇2𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼 − ∇ ∙ �𝜐𝜐𝐸𝐸𝐸𝐸𝐼𝐼𝐯𝐯𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼� + 𝜐𝜐𝐸𝐸𝐸𝐸𝐼𝐼𝐸𝐸𝐸𝐸�𝐶𝐶𝐹𝐹,𝐼𝐼𝐼𝐼𝐼𝐼,𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼� − 𝜐𝜐𝐸𝐸𝐸𝐸𝐼𝐼𝑘𝑘𝐹𝐹,𝑒𝑒𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼 − 𝜐𝜐𝐼𝐼𝐸𝐸𝐼𝐼𝑘𝑘𝐹𝐹,𝑒𝑒𝐶𝐶𝐹𝐹,𝐼𝐼𝐸𝐸𝐼𝐼 − 𝜕𝜕𝐶𝐶𝐵𝐵𝜕𝜕𝑡𝑡  (6) 
where 𝜐𝜐 refers to the volume fraction of each tissue compartment and kF,e is the drug’s elimination 
rate due to the drug physical degradation and metabolic reactions. 
The two-way exchange of free doxorubicin between IVS and ECS is determined by the 
convective transport with fluid loss from blood and diffusion driven by the transvascular 
concentration gradient. 
𝐸𝐸𝐸𝐸�𝐶𝐶𝐹𝐹,𝐼𝐼𝐼𝐼𝐼𝐼,𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼� = �𝐹𝐹𝑏𝑏(1 − 𝜎𝜎𝐹𝐹)𝐶𝐶𝐹𝐹,𝐼𝐼𝐼𝐼𝐼𝐼 + 𝑃𝑃𝐹𝐹 𝑆𝑆𝑉𝑉 �𝐶𝐶𝐹𝐹,𝐼𝐼𝐼𝐼𝐼𝐼 − 𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼� PeF𝐷𝐷PeF − 1� (7) 
where 𝑃𝑃𝐹𝐹  is the transvascular permeability of free doxorubicin, which is a function of time when the 
FUS-MB induced BBBD takes place. The Péclet number (PeF) is defined as PeF = 𝐹𝐹𝑏𝑏(1−𝜎𝜎𝐹𝐹)𝑃𝑃𝐹𝐹𝐼𝐼 𝐼𝐼⁄ . 
Two assumptions are further involved at this point: (I) the dynamic equilibrium of free 
doxorubicin concentration can be achieved in different tissue compartments [24] ( 𝑃𝑃𝐼𝐼𝐸𝐸𝐼𝐼−𝐸𝐸𝐸𝐸𝐼𝐼 =
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𝐶𝐶𝐹𝐹,𝐼𝐼𝐸𝐸𝐼𝐼 𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼⁄ ; 𝑃𝑃𝐸𝐸𝐶𝐶−𝐸𝐸𝐸𝐸𝐼𝐼 = 𝐶𝐶𝐹𝐹,𝐸𝐸𝐶𝐶 𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼⁄ ) and (II) the concentration of bound drug is linearly related to 
that of the drug in its free from [20] (𝐾𝐾𝐸𝐸𝐸𝐸𝐼𝐼 = 𝐶𝐶𝐵𝐵,𝐸𝐸𝐸𝐸𝐼𝐼 𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼⁄ ; 𝐾𝐾𝐼𝐼𝐸𝐸𝐼𝐼 = 𝐶𝐶𝐵𝐵,𝐼𝐼𝐸𝐸𝐼𝐼 𝐶𝐶𝐹𝐹,𝐼𝐼𝐸𝐸𝐼𝐼⁄ ). Equation (6) can thus 
be rewritten as 
𝜕𝜕𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼
𝜕𝜕𝑡𝑡
= 𝐷𝐷𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼∗ ∇2𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼 − 𝐯𝐯∗ ∙ ∇𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼 − 𝑘𝑘𝐹𝐹,𝑒𝑒∗ 𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼 + 𝐸𝐸𝐸𝐸∗�𝐶𝐶𝐹𝐹,𝐼𝐼𝐼𝐼𝐼𝐼,𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼� (8) 
where 𝐯𝐯∗ = (𝜐𝜐𝐸𝐸𝐸𝐸𝐼𝐼 𝜔𝜔⁄ )𝐯𝐯 is the apparent velocity of interstitial fluid flow, 𝐷𝐷𝐹𝐹 ,𝐸𝐸𝐸𝐸𝐼𝐼∗ = (𝜐𝜐𝐸𝐸𝐸𝐸𝐼𝐼 𝜔𝜔⁄ )𝐷𝐷𝐹𝐹 ,𝐸𝐸𝐸𝐸𝐼𝐼 is 
the apparent diffusion coefficient of free drug, 𝑘𝑘𝐹𝐹,𝑒𝑒∗ = �(𝜐𝜐𝐸𝐸𝐸𝐸𝐼𝐼 + 𝜐𝜐𝐼𝐼𝐸𝐸𝐼𝐼)𝑘𝑘𝐹𝐹,𝑒𝑒 + 𝐹𝐹𝑏𝑏� 𝜔𝜔⁄  refers to the 
apparent drug elimination rate in tissue, 𝐸𝐸𝐸𝐸∗�𝐶𝐶𝐹𝐹,𝐼𝐼𝐼𝐼𝐼𝐼,𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼� = 𝜐𝜐𝐸𝐸𝐸𝐸𝐼𝐼𝐸𝐸𝐸𝐸�𝐶𝐶𝐹𝐹,𝐼𝐼𝐼𝐼𝐼𝐼,𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼� 𝜔𝜔⁄  is the apparent 
drug exchange between IVS and ECS in both the brain tumour and normal tissue and 𝜔𝜔 is defined 
as 𝜔𝜔 = 𝜐𝜐𝐸𝐸𝐸𝐸𝐼𝐼(1 + 𝐾𝐾𝐸𝐸𝐸𝐸𝐼𝐼) + 𝜐𝜐𝐼𝐼𝐸𝐸𝐼𝐼𝑃𝑃𝐼𝐼𝐸𝐸𝐼𝐼−𝐸𝐸𝐸𝐸𝐼𝐼(1 + 𝐾𝐾𝐼𝐼𝐸𝐸𝐼𝐼) + (1 − 𝜐𝜐𝐸𝐸𝐸𝐸𝐼𝐼 − 𝜐𝜐𝐼𝐼𝐸𝐸𝐼𝐼)𝑃𝑃𝐸𝐸𝐶𝐶−𝐸𝐸𝐸𝐸𝐼𝐼. 
2.1.3. Delivery of Liposome-Encapsulated Doxorubicin 
The drug transport in liposome-mediated delivery via intravenous administration is 
schematically shown in Figure 2. The pharmacokinetics of liposome-encapsulated doxorubicin 
(𝐶𝐶𝐿𝐿,𝐼𝐼𝐼𝐼𝐼𝐼) can be expressed as 
𝐶𝐶𝐿𝐿,𝐼𝐼𝐼𝐼𝐼𝐼 = 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝑉𝑉𝐿𝐿,𝑑𝑑 𝐷𝐷−�𝑘𝑘𝐿𝐿,𝑐𝑐+𝑘𝑘𝑟𝑟𝑟𝑟𝑟𝑟�𝑡𝑡 (9) 
in which 𝑉𝑉𝐿𝐿,𝑑𝑑  is the distribution volume of liposomes and 𝑘𝑘𝐿𝐿,𝑐𝑐  is the plasma clearance rate. 𝑘𝑘𝑟𝑟𝑒𝑒𝑟𝑟  
denotes the drug release rate. 
 
Figure 2. Drug transport in liposome-mediated delivery combined with FUS-MB-induced BBBD. The 
red dashed line refers to the disrupted BBB, and the enhanced transvascular transport is highlighted 
in green. 
The extracellular concentration of liposomal doxorubicin (𝐶𝐶𝐿𝐿,𝐸𝐸𝐸𝐸𝐼𝐼) can be calculated by 
𝜕𝜕𝐶𝐶𝐿𝐿,𝐸𝐸𝐸𝐸𝐼𝐼
𝜕𝜕𝑡𝑡
= 𝐷𝐷𝐿𝐿,𝐸𝐸𝐸𝐸𝐼𝐼∇2𝐶𝐶𝐿𝐿,𝐸𝐸𝐸𝐸𝐼𝐼 − ∇ ∙ �𝐯𝐯𝐶𝐶𝐿𝐿,𝐸𝐸𝐸𝐸𝐼𝐼� − 𝑘𝑘𝑟𝑟𝑒𝑒𝑟𝑟𝐶𝐶𝐿𝐿,𝐸𝐸𝐸𝐸𝐼𝐼 + 𝐸𝐸𝐸𝐸�𝐶𝐶𝐿𝐿,𝐼𝐼𝐼𝐼𝐼𝐼,𝐶𝐶𝐿𝐿,𝐸𝐸𝐸𝐸𝐼𝐼� (10) 
where 𝐷𝐷𝐿𝐿,𝐸𝐸𝐸𝐸𝐼𝐼 is the diffusion coefficient of liposomes in tissue ECS. 𝐸𝐸𝐸𝐸�𝐶𝐶𝐿𝐿,𝐼𝐼𝐼𝐼𝐼𝐼,𝐶𝐶𝐿𝐿,𝐸𝐸𝐸𝐸𝐼𝐼� is defined in 
the same way as in Equation (7). 
The intravascular concentration of free doxorubicin (𝐶𝐶𝐹𝐹,𝐼𝐼𝐼𝐼𝐼𝐼) is determined by the transvascular 
exchange between IVS and tissue ECS, drug release from liposomes, binding with proteins and 
plasma clearance. 
𝜕𝜕𝐶𝐶𝐹𝐹,𝐼𝐼𝐼𝐼𝐼𝐼
𝜕𝜕𝑡𝑡
= 𝑘𝑘𝑟𝑟𝑒𝑒𝑟𝑟𝐶𝐶𝐿𝐿,𝐼𝐼𝐼𝐼𝐼𝐼 − 𝑉𝑉𝑡𝑡𝑖𝑖𝑡𝑡𝑡𝑡𝑡𝑡𝑒𝑒𝑉𝑉𝐹𝐹,𝑑𝑑 𝐸𝐸𝐸𝐸�𝐶𝐶𝐹𝐹,𝐼𝐼𝐼𝐼𝐼𝐼,𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼� − 𝑘𝑘𝐹𝐹,𝑐𝑐𝐶𝐶𝐹𝐹,𝐼𝐼𝐼𝐼𝐼𝐼 − 𝜕𝜕𝐶𝐶𝐵𝐵,𝐼𝐼𝐼𝐼𝐼𝐼𝜕𝜕𝑡𝑡  (11) 
where 𝑉𝑉𝑡𝑡𝑖𝑖𝑡𝑡𝑡𝑡𝑡𝑡𝑒𝑒  is the volume of either brain tumour or its surrounding tissue. The extracellular 
concentration of free doxorubicin (𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼) is governed by 
𝜕𝜕𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼
𝜕𝜕𝑡𝑡
= 𝐷𝐷𝐹𝐹 ,𝐸𝐸𝐸𝐸𝐼𝐼∗ ∇2𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼 − 𝐯𝐯∗ ∙ ∇𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼 − 𝑘𝑘𝐹𝐹,𝑒𝑒∗ 𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼 + 𝐸𝐸𝐸𝐸∗�𝐶𝐶𝐹𝐹,𝐼𝐼𝐼𝐼𝐼𝐼,𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼� + 𝑘𝑘𝑟𝑟𝑒𝑒𝑟𝑟∗ 𝐶𝐶𝐿𝐿,𝐸𝐸𝐸𝐸𝐼𝐼 (12) 
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where 𝑘𝑘𝑟𝑟𝑒𝑒𝑟𝑟∗ = 𝑘𝑘𝑟𝑟𝑒𝑒𝑟𝑟 𝜔𝜔⁄  refers to the apparent drug release rate from liposomes. 
2.2. Model Geometry 
The 3D geometrical model of a brain tumour and surrounding normal tissue was reconstructed 
from anonymous MR images, which were acquired in three orthogonal planes. These images were 
stored on the image database TCIA, and are available for scientific purposes under a Creative 
Commons Attribution 3.0 Unported License [25,26]. Each image slice was 1 mm thick, and comprised 
256 × 256 pixels. The dimension of each pixel was also 1 mm. Figure 3A shows a representative image 
slice as used in this study. 
 
Figure 3. Model geometry. (A) MR image, and (B) reconstructed 3D geometry of brain tumour (orange) 
and its surrounding normal tissue (grey). The brain ventricle is coloured in cyan. 
The brain tumour, ventricle and normal tissue were segmented based on the local signal 
intensity on each image slice using MIMICS (Materialise HQ, Leuven, Belgium). After being 
smoothed, these reconstructed 3D surfaces were imported into ANSYS ICEM CFD (ANSYS Inc., 
Canonsburg, PA, USA) to generate the computational mesh. The final volumetric mesh was 
composed of 4.6 million tetrahedral elements, which were tested to be fine enough to eliminate the 
grid-quality dependence. The 3D model geometry is shown in Figure 3B, where the volume of the 
brain tumour and its surrounding tissue were 2.47 × 10−5 m3 and 1.39 × 10−3 m3, respectively. 
2.3. Model Parameters 
Given that the simulation time window was much shorter than that of tumour growth, the 
biological and geometrical properties of brain tumour and normal tissue, as well as the transport 
properties of anticancer agents, were treated as being independent of time [17]. The baseline value of 
each parameter with respect to its category is listed in Tables 1 and 2. In contrast to doxorubicin, 
which is unable to penetrate the BBB alone [6,7], surface modification with certain ligands 
successfully improves the liposome transvascular transport in brain tumour [27,28]. Therefore, the 
transvascular permeability of doxorubicin was assumed to be zero without BBBD, while the innate 
permeability of liposomes was set as 3.4 × 10−9 m/s [29] in the brain tumour. 
Drug transvascular permeation upon BBBD can be described by an exponential decay function 
[21] as follows. 
𝑃𝑃(𝑡𝑡) = � 𝑃𝑃0 + 𝑃𝑃𝑡𝑡 𝑡𝑡 < 𝑇𝑇𝑡𝑡
𝑃𝑃0 + 𝑃𝑃𝑡𝑡exp[−𝑘𝑘𝑟𝑟(𝑡𝑡 − 𝑇𝑇𝑡𝑡)] 𝑡𝑡 ≥ 𝑇𝑇𝑡𝑡 (13) 
where 𝑃𝑃0 is the drug instinct transvascular permeability and 𝑃𝑃𝑡𝑡 refers to the enhancement due to 
the BBBD. 𝑇𝑇𝑡𝑡 is the sonication duration. For the small molecular drugs like free doxorubicin, the 
enhanced permeability correlates to its molecular weight (𝑀𝑀𝑀𝑀) [21]: 
𝑃𝑃𝐶𝐶𝑀𝑀 𝑃𝑃Gd−DPTA⁄ = 1 − 0.5lg(𝑀𝑀𝑀𝑀) (14) 
in which 𝑃𝑃Gd−DPTA is the transvascular permeability of Gd-DPTA, which was measured to be 2.0 × 
10−6 m/s [30] when 0.6 MPa FUS was applied. Under similar sonication conditions, the transvascular 
permeability of 120 nm liposomes was about 4.25 times higher than the baseline value [31]. 𝑘𝑘𝑟𝑟 stands 
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for the BBBD recovery rate, which can be calibrated using the semi-empirical formula [32] 
𝑘𝑘𝑟𝑟 = 𝑙𝑙𝑙𝑙2(1 + 0.21𝑑𝑑𝐻𝐻2 ) 2.34 × 104⁄  (15) 
where 𝑑𝑑𝐻𝐻 is the hydrodynamic diameter (in nm) of the anticancer agents, and can be predicted based 
on the Einstein–Stokes equation [32]. 
Table 1. Parameters for chemotherapeutic drugs *. 
Symbol Parameter Unit Liposome Doxorubicin 
PICS-ECS Partition coefficient between ICS and ECS - - 1.0 [33] 
PCM-ECS Partition coefficient between CM and ECS - - 0.3 [34] 
KIVS, KECS, KICS Binding constant in IVS, ECS and ICS - - 3.0 [35] 
DECS Diffusion coefficient in tissue ECS m2/s 
9.0 × 10−12 (T) [36] 
5.8 × 10−12 (N) [36] 
3.4 × 10−10 (T) [17] 
1.6 × 10−10 (N) [17] 
P0 Transvascular permeability with BBBD m/s 3.4 × 10
−9 (T) [29] 
0.0 (N) 
0.0 (T)  
0.0 (N) 
σ Drug osmotic reflection coefficient  - 
0.95 (T) [37] 
1.0 (N) [37] 
0.15 (T) [17] 
0.15 (N) [17] 
ke Drug elimination rate in tissue s−1 - 5.8 × 10−4 [17] 
kc Drug clearance rate in blood s−1 3.9 × 10−6 [38] 2.4 × 10−3 [39] 
krel Drug release rate from liposomes  s−1 1.0 × 10−4 [40] - 
Vd Distribution volume m3 6.4 × 10−3 [36] 7.7 × 10−3 [39] 
* T and N refer to the brain tumour and normal brain tissue, respectively. 
Table 2. Parameters for the brain tumour and normal tissue. 
Symbol Parameter Unit Brain Tumour Normal Tissue 
α Volume fraction of ECS - 0.35 [41] 0.20 [33] 
β Volume fraction of ICS - 0.55 [41] 0.65 [33] 
ρ Density of interstitial fluid kg/m3 1.0 × 103 [42] 1.0 × 103 [42] 
μ Viscosity of interstitial fluid kg/m/s 7.8 × 10−4 [42] 7.8 × 10−4 [42] 
πb Osmotic pressure of blood Pa 3.4 × 103 [43] 3.4 × 103 [43] 
πi Osmotic pressure of interstitial fluid Pa 1.1 × 103 [12] 7.4 × 102 [12] 
pb Pressure in intravascular space Pa 4.6 × 103 [43] 4.6 × 103 [43] 
S/V Area of blood vessel surface per tissue volume m−1 2.0 × 104 [12] 7.0 × 103 [12] 
σT Osmotic reflection coefficient of tissue - 0.82 [12] 0.91 [12] 
Kb Hydraulic conductivity of blood vessel wall m/Pa/s 1.1 × 10−12 [16] 1.4 × 10−13 [16] 
κ Tissue Darctian permeability m2 6.4 × 10−14 [16] 6.5 × 10−15 [16] 
2.4. Numerical Methods 
The mathematical model was implemented in ANSYS FLUENT (ANSYS Inc., Canonsburg, PA, 
USA) for numerical solutions. The predicted pressure and velocity correction were correlated by the 
SIMPLEC algorithm. The second-order implicit Euler scheme and second-order UPWIND scheme 
were employed to achieve temporal and spatial discretisation of governing equations, respectively. 
The residual tolerance was set as 1 × 10−5 to control the simulation convergence, and the time step was 
fixed at 10 s to achieve the time-step-independent solutions. The governing equations for interstitial 
fluid flow were solved first to generate the hydraulic environment in the steady state. The obtained 
pressure and velocity were then imported into the submodules of drug transport at time zero to 
predict the drug delivery processes [44–46]. Drug concentration was assumed to be zero throughout 
the whole domain at the beginning of treatment. 
  
Pharmaceutics 2020, 12, 69 7 of 21 
 
2.5. Boundary Conditions 
The gauge pressure on the brain surface and ventricle were specified as 658 Pa [47] and 1447 Pa 
[43], respectively, with zero flux of drug. The continuity condition [17] was applied at the interface 
between the tumour and normal tissue. 
2.6. Quantification of Delivery Outcomes 
The drug bioavailability for anticancer effectiveness and risk of cardiotoxicity was measured as 
the drug exposure over time (𝐴𝐴𝐴𝐴𝐶𝐶), which is defined as 
𝐴𝐴𝐴𝐴𝐶𝐶𝑇𝑇 = � 𝐶𝐶(𝑡𝑡)𝑑𝑑𝑡𝑡𝑇𝑇
0
 (16) 
where the 𝑇𝑇 is the considered period of treatment. 
3. Results 
3.1. Interstitial Fluid Flow 
As the drug convective and diffusive transport in tissue ECS are both dependent on the 
interstitial fluid, its flow field was expected to play an important role in determining the delivery 
outcomes. In this study, the interstitial fluid flow was predicted by solving the governing Equations 
(1)–(3) throughout the entire brain, subject to the biological properties and the boundary conditions 
described above. 
The spatial distribution of interstitial fluid pressure (IFP) on a brain cross-section is shown in 
Figure 4A. IFP reduced gradually from the ventricle to brain surface. However, this pressure was 
higher in the tumour, as shown in Table 3. This was attributed to the variation of microvasculature 
in tumour tissue; on one hand, the vasculature surface is enlarged, since the microvasculature 
becomes tortuous and elongated. On the other hand, large pores on vessel surfaces can significantly 
increase the hydraulic conductivity of the blood vessels, enhancing fluid leakage into the tumour 
ECS. 
 
Figure 4. Predicted (A) interstitial fluid pressure and (B) velocity in the brain. Results are shown on a 
cross-section that covers regions of brain tumour, normal brain tissue and ventricle. 
Table 3. Predicted interstitial fluid flow. 
Tissue Type 𝑰𝑰𝑰𝑰𝑰𝑰𝒂𝒂𝒂𝒂𝒂𝒂 (Pa) 𝑰𝑰𝑰𝑰𝑰𝑰𝒂𝒂𝒂𝒂𝒂𝒂 (μm/s) 
Brain tumour 1071.79 0.43 
Normal tissue 876.03 0.13 
As shown in Figure 4B, the interstitial fluid flows across the entire brain from ventricle to brain 
surface, driven by the pressure gradient in the same direction. The comparisons presented in Table 3 
denote that the interstitial fluid flow was faster in the brain tumour. This was due to the advanced 
fluid loss from blood [48] and the high hydraulic conductivity of the tumour tissue [49]. As a result, 
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the drug convective transport was more effective in tumour. It is worth noting that the interstitial 
fluid velocity (IFV) was not uniform in the tumour. Due to the large pressure difference between the 
tumour and the brain surface, the velocity was higher in the tumour region, which was more 
superficial. 
3.2. Baseline Study of Drug Transport and Accumulation 
A total dose of 50 mg/m2 liposomal doxorubicin was administrated into a 70 kg patient’s 
circulatory system by bolus injection [17]. The FUS sonication and MB injection were supposed to 
start simultaneously with the chemotherapy, and to last for seconds [50–52]. This sonication duration 
was negligible, as it was short compared to the examined treatment duration of 24 h [21]. 
Figure 5 shows the predicted doxorubicin concentrations in each tissue compartment as a 
function of time. As the liposomes were injected into the blood stream over a very short duration 
(bolus injection), the intravascular concentration of liposomal doxorubicin concentration (𝐶𝐶𝐿𝐿,𝐼𝐼𝐼𝐼𝐼𝐼) 
peaked when the treatment started and decreased exponentially over time. Free doxorubicin 
concentration in IVS (𝐶𝐶𝐹𝐹,𝐼𝐼𝐼𝐼𝐼𝐼) continued to increase in the first 1.5 h as a result of the continuous drug 
release from the liposomes. This was followed by a gradual decline owing to the decrease of 𝐶𝐶𝐿𝐿,𝐼𝐼𝐼𝐼𝐼𝐼 
and the continuous drug plasma clearance. Liposomal doxorubicin continued to accumulate in 
tumour ECS until the 2 h point, driven by the transvascular concentration gradient. However, due to 
the reduction of this gradient and drug release, less doxorubicin could remain in the encapsulated 
form in tumour ECS as time went on. Since local drug release and the exchange with IVS were the 
two sources for free doxorubicin to accumulate in the tumour ECS, 𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼 reached its peak around 
3.5 h after the treatment started, with a time delay of 2 h compared to 𝐶𝐶𝐹𝐹,𝐼𝐼𝐼𝐼𝐼𝐼. 
 
Figure 5. The concentration of doxorubicin in different forms in (A) each compartment of the brain 
tumour and the surrounding normal tissue. A close look in normal tissue is given in (B). 
A close look at the doxorubicin concentration in normal tissue is given in Figure 5B, where the 
drug presented similar trends as in the tumour ECS. However, the concentrations were about three 
orders of magnitude lower. This is because the drug reached the normal tissue from the tumour by 
convective and diffusive transport. 
3.3. Comparisons to other Delivery Modes 
The delivery outcomes are compared to those of two control studies using the same dose and 
administration method in Figure 6. These control studies were specified as (I) direct delivery of free 
doxorubicin with BBBD, and (II) liposome-mediated delivery of doxorubicin without BBBD. 
When the drug was directly administered in its free form, 𝐶𝐶𝐹𝐹,𝐼𝐼𝐼𝐼𝐼𝐼 reached its peak at the 
beginning of treatment and decreased sharply to zero in about 1 h. In contrast, liposome-mediated 
delivery effectively reduced the drug clearance via the blood, resulting in a gradual change of 𝐶𝐶𝐹𝐹,𝐼𝐼𝐼𝐼𝐼𝐼 
over time. Since BBBD does not affect the pharmacokinetics of liposomes and the dynamics of drug 
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release, 𝐶𝐶𝐹𝐹,𝐼𝐼𝐼𝐼𝐼𝐼 presented a similar time courses to liposome-mediated delivery both with and without 
BBBD. 
 
Figure 6. The time course of free doxorubicin concentration under different delivery modes. (A) IVS, 
(B) tumour ECS and (C) normal tissue ECS. 
Free doxorubicin concentration in tumour ECS (𝐶𝐶𝐹𝐹,𝐸𝐸𝐸𝐸𝐼𝐼) was strongly dependent on the delivery 
mode. Although BBBD successfully enabled doxorubicin to cross the blood vessel wall, the drug 
accumulation was less effective in the treatment where free doxorubicin was directly administrated. 
This can be attributed to the fast decreases of IVS concentration and drug transvascular transport, as 
shown in Figures 6A and 7B, respectively. In contrast, the combination of BBBD and liposome-
mediated delivery significantly improve the drug accumulation in tumour tissue. The drug 
concentration in normal tissue showed similar trends as in tumour ECS; however, the magnitude is 
three orders lower. 
 
Figure 7. The transvascular flux of (A) liposome-encapsulated doxorubicin and (B) free doxorubicin 
between IVS and ECS in the brain tumour. 
The impacts of BBBD on the drug transvascular flux are shown in Figure 7. The comparisons 
indicated that the transvascular transport of liposome-encapsulated doxorubicin was less sensitive 
to BBBD. This was due to the fast BBBD recovery, for which half-life time was 7.74 s, as predicted by 
Equation (15) from Reference [32]. 
BBBD greatly affected the transport of free doxorubicin across the vessel wall. The flux under 
direct injection was three orders of magnitude higher. However, it decreased to negative in about 30 
min, implying that the free doxorubicin began to be transported back from tumour ECS to IVS as the 
concentration gradient reversed, so that more drug was lost from the tumour ECS. In contrast, free 
doxorubicin in liposome-mediated delivery continued to pass through the vessel wall to the tumour 
ECS for 4 h. The drug accumulation in tumour ECS was therefore improved, as shown in Figure 6B. 
It is worth noting that the transvascular flux of free doxorubicin remained zero throughout the entire 
treatment when using liposomes alone. This is because no free doxorubicin could cross the blood 
vessel wall without BBBD. 
The outcomes of the different delivery modes are compared in Table 4 in terms of the drug 
exposure over time (AUC). It is defined as the area under the curve of free drug concentration against 
time. The comparisons show that the combination of BBBD and liposome-mediated delivery 
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successfully improved the bioavailability of doxorubicin in each compartment of the brain. Although 
more effective drug exposure in tumours could improve the drug’s anticancer efficacy, additional 
attention is required as the increased drug concentration in the blood circulatory system and normal 
brain tissue could raise the risk of adverse effects. 
Table 4. AUC24h (mg/mL·s) with different delivery modes. 
Delivery Mode IVS Tumour ECS Normal Tissue ECS 
Direct administration + BBBD 3.47 1.37 2.54 × 10−3 
Liposomes 17.78 9.68 1.07 × 10−2 
Liposomes + BBBD 17.78 12.95 1.79 × 10−2 
3.4. Impact of Release Rate 
As the representative value of the time scale on which the liposomes released the loaded drug, 
release rate directly determines the toxicity and anticancer activity of a drug-delivery system [53–55]. 
It can vary across a wide range, depending on several factors such as the liposome formulation, 
fabrication approach, surrounding environment [56,57], etc. Sustainable release over weeks can be 
achieved using stealth liposomes [58], while temperature-sensitive liposomes are designed to release 
their loads in seconds to minutes [59]. Therefore, the release rate was changed within the range from 
1 × 10−6·s−1 to 1 × 10−3·s−1 in this study. 
The impacts of the release rate on doxorubicin concentrations are shown in Figure 8. It is not 
surprising that a slow drug release kept more doxorubicin in the encapsulated form in the blood, and 
thereby was able to provide a sustainable drug supply. A similar response was found for the liposome 
concentration in tumour ECS (𝐶𝐶𝐿𝐿,𝐸𝐸𝐸𝐸𝐼𝐼 ). This is because, on one hand, a high 𝐶𝐶𝐿𝐿,𝐼𝐼𝐼𝐼𝐼𝐼  enabled the 
liposome-encapsulated drug to enter the tumour ECS in a continuous manner; on the other hand, the 
reduced 𝑘𝑘𝑟𝑟𝑒𝑒𝑟𝑟  slowed down the drug release in tumour tissue. The 𝐶𝐶𝐿𝐿,𝐸𝐸𝐸𝐸𝐼𝐼  in normal tissue had a 
similar sensitivity to the release rate, but it was orders of magnitude lower than in tumour tissue. 
 
Figure 8. The time courses of doxorubicin concentration in treatments using liposomes with different 
release rates. Liposome-encapsulated doxorubicin in (A) IVS, (B) tumour and (C) normal tissue ECS; 
free doxorubicin in (D) IVS, (E) tumour and (F) normal tissue ECS. 
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Results also showed that reducing the release rate could effectively lower the concentration peak 
of free doxorubicin, and lead to a more gradual variation of drug concentration with time. Although 
fast release could sharply raise the amount of free doxorubicin in a short period time, more drug was 
cleared out of the tumour due to the high elimination rates in both blood and tissue ECS, as shown 
in Table 1. Moreover, since there was no longer enough drug being released from liposomes, the 
concentration of free doxorubicin dropped quickly to a low level. 
The transvascular fluxes of doxorubicin in the treatment using different liposomes are plotted 
in Figure 9. Owing to the reduced availability, less liposomal drug could cross the blood vessel wall 
when the release rate was increased. In contrast, the transvascular flux of free doxorubicin became 
more volatile with the increase of release rate. As more free drug was released, the high 𝑘𝑘𝑟𝑟𝑒𝑒𝑟𝑟  could 
significantly increase the transvascular concentration gradient after the treatment started. 
Consequentially, large amounts of free drug were transported into the tumour ECS. However, due 
to the fast decrease of 𝐶𝐶𝐹𝐹,𝐼𝐼𝐼𝐼𝐼𝐼, as shown in Figure 8D, this transvascular flux fell quickly to negative 
when the free doxorubicin concentration in blood became lower than in tumour ECS. The 
transvascular flux gradually restored as time proceeded, as drug was slowly transported back to the 
blood. 
 
Figure 9. The time courses of drug transvascular flux in the treatments using liposomes with different 
release rates. (A) Liposome-encapsulated doxorubicin and (B) free doxorubicin. 
The delivery outcomes using liposomes with different release rates are compared in Table 5. The 
availability of free drug in the IVS increased with the release rate, whereas the drug exposure in tissue 
ECS was non-linearly correlated to the release rate in the examined period. This finding indicates that 
the drug release rate can be optimised to maximise the treatment efficacy while maintaining a similar 
risk of side effects to the cardiovascular system. 
Table 5. AUC24h (mg/mL·s) of the treatments using liposomes with different release rates. 
Release Rate (s−1) IVS Tumour ECS Normal Tissue ECS 
krel = 1.0 × 10−6 1.28 × 10−3 1.39 × 10−3 3.83 × 10−6 
krel = 1.0 × 10−5 9.20 × 10−3 9.69 × 10−3 2.44 × 10−5 
krel = 1.0 × 10−4 1.78 × 10−2 1.29 × 10−2 1.79 × 10−5 
krel = 1.0 × 10−3 1.83 × 10−2 7.98 × 10−3 9.96 × 10−6 
3.5. Impact of BBBD Timing 
The starting time point of BBBD is a factor that can be well controlled in clinical operations. The 
BBB was disrupted simultaneously with the liposome injection in the baseline study. The delivery 
outcomes were compared to those of treatments in which BBBD was induced at 30, 60 and 90 min 
after the chemotherapy started, as shown in Figure 10. Given that the BBBD has no effect on liposome 
pharmacokinetics and release dynamics, identical time courses of 𝐶𝐶𝐿𝐿,𝐼𝐼𝐼𝐼𝐼𝐼 and 𝐶𝐶𝐹𝐹,𝐼𝐼𝐼𝐼𝐼𝐼 were found in 
each treatment. Although the liposomes presented similar concentration profiles in the brain tumour, 
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less free doxorubicin was available for cell killing when the BBB opening was postponed. This was 
the same in normal tissue, since all the drug came from tumour ECS by convection and diffusion. 
 
Figure 10. The time courses of doxorubicin concentrations in treatments with different BBBD timing. 
Liposome-encapsulated doxorubicin in (A) IVS, (B) tumour and (C) normal tissue ECS; free 
doxorubicin in (D) IVS, (E) tumour and (F) normal tissue ECS. 
The transvascular flux in treatments with different sonication timings is shown in Figure 11. 
Results showed that the transvascular flux of liposomes was reduced by postponing the BBBD. 
However, since the enhanced 𝑃𝑃𝐿𝐿  dropped quickly to its normal level, changing the BBBD timing had 
no obvious impact on the liposome ECS concentration in tumour tissue, as shown in Figure 10B. 
 
Figure 11. The time courses of drug transvascular flux in the treatments with different BBBD timings. 
(A) Liposome-encapsulated doxorubicin and (B) free doxorubicin. 
This was different from free doxorubicin—its transvascular flux jumped to a higher peak during 
BBBD; however, it must be noted that there was no exchange of free doxorubicin between blood and 
tumour tissue before the BBBD occurred. As a result, the transvascular flux over the entire treatment 
period was low, and the free doxorubicin accumulation in tumour tissue was therefore reduced, as 
shown in Figure 10E. 
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The delivery outcomes compared in Table 6 show that for liposome-mediated delivery by bolus 
injection, reduction of anticancer effectiveness could be introduced when BBBD is postponed. 
However, the risk of adverse effects to the cardiovascular system remain similar. 
Table 6. AUC24h (mg/mL·s) of the treatments with different BBBD timings. 
Delay (min) IVS Tumour ECS Normal Tissue ECS 
0 min 1.78 × 10−2 1.29 × 10−2 1.79 × 10−5 
30 min 1.78 × 10−2 1.27 × 10−2 1.77 × 10−5 
60 min 1.78 × 10−2 1.19 × 10−2 1.73 × 10−5 
90 min 1.78 × 10−2 1.12 × 10−2 1.69 × 10−5 
3.6. Impact of Sonication Duration 
The time window of FUS sonication is another controllable factor in clinical settings. It usually 
lasts for seconds in preclinical trials [50–52], whereas a 40 min sonication was applied in a previous 
in vivo experiment to increase doxorubicin delivery [60]. Hence, the delivery with FUS sonication for 
15, 30 and 45 min was compared to the baseline study to examine the effects of this factor. 
The doxorubicin concentration in treatments with different sonication durations are shown in 
Figure 12. Given that BBBD has no impact on liposome transport within blood, the encapsulated 
doxorubicin presented the same time course for IVS concentration in different treatments. Similar 
trends were found for free doxorubicin IVS concentration, as this mainly determined by local drug 
release and plasma clearance which are both independent of BBBD. In contrast, the drug 
concentrations in tumour and normal tissue ECS were increased by prolonging the FUS sonication. 
 
Figure 12. The time courses of doxorubicin concentrations in treatments with different sonication 
durations. Liposome-encapsulated doxorubicin in (A) IVS, (B) tumour and (C) normal tissue ECS; 
free doxorubicin in (D) IVS, (E) tumour and (F) normal tissue ECS. 
The impacts of sonication duration on the drug transvascular flux are given in Figure 13 as a 
function of time. Results showed that the IVS–ECS exchange of liposomal doxorubicin began to 
decline after the treatment started. However, this decline could be effectively slowed down by 
prolonging the FUS sonication, due to the enhanced liposome transvascular permeability. 
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Consequentially, more liposomes were able to accumulate in the tumour ECS, as shown in Figure 
12B. A sharp fall was observed after the sonication ended, because of the fast recovery of BBBD to 
liposomes [32]. 
 
Figure 13. The time courses of drug transvascular flux in the treatments with different sonication 
durations. (A) Liposome-encapsulated doxorubicin and (B) free doxorubicin. 
Prolonging the sonication duration had limited impact on the gain of free drug from the blood, 
but resulted in the increase of drug loss by blood drainage. This is because the BBBD-enhanced 𝑃𝑃𝐹𝐹  
remained at a higher level for free doxorubicin transport back to the blood. As a result, the improved 
drug release from liposomes was assumed to be the main reason for the effective free drug 
accumulation in tumour ECS shown in Figure 12E. 
Table 7 compares the delivery outcomes of treatments with different sonication durations. 
Results showed that the anticancer efficacy could be successfully improved by increasing the FUS 
functioning time window. Simultaneously, the risk of adverse effects to brain normal tissue could 
also be increased. However, the similar drug availability in blood indicates that the sonication 
duration would have limited effects on the risk of cardiotoxicity. 
Table 7. AUC24h (mg/mL·s) of the treatments with different sonication durations. 
Sonication Duration (min) IVS Tumour ECS Normal Tissue ECS 
Burst 1.78 × 10−2 1.29 × 10−2 1.79 × 10−5 
15 min 1.78 × 10−2 1.48 × 10−2 2.02 × 10−5 
30 min 1.78 × 10−2 1.61 × 10−2 2.19 × 10−5 
45 min 1.78 × 10−2 1.70 × 10−2 2.31 × 10−5 
4. Discussion 
FUS and MB can successfully open the BBB, and thereby enable doxorubicin accumulation in 
tumour ECS for treatment. Modelling predictions further demonstrated that liposome-encapsulated 
drugs could effectively improve the delivery outcomes of combination therapy with FUS and MB. 
Owing to the fast recovery of BBBD to liposomes, burst FUS sonication had very limited impact on 
the transvascular transport of liposomal drug, as shown in Figure 7A. Therefore, the advantage of 
the FUS-MB-liposome combined delivery was mainly due to the improved transvascular 
permeability of free doxorubicin and sustainable drug supply by the long-circulating liposomes. 
In order to examine the impact of enhanced liposome transvascular permeability on the delivery 
outcomes, the sonication duration was prolonged up to 45 min. Although the loss of free doxorubicin 
by capillary drainage was slightly raised, as shown in Figure 13, the modelling results showed that 
keeping the BBB open for a longer time effectively improved the accumulation of both the liposome-
encapsulated and free doxorubicin, which could lead to better therapy. However, it is important to 
note that the enhancement of drug transvascular permeability is very limited when FUS is applied in 
isolation [31]. Therefore, the pharmacokinetics of MB must be considered in treatment design in order 
to achieve continuous BBBD. Since sonication has been generally performed for few seconds in 
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preclinical trials, how to prolong FUS sonication and MB circulation for continuous BBBD needs to 
be explored in both experiments and simulations in the future. 
Serval factors influence BBBD, including the frequency and power of FUS [61–63], sonication 
schedule [21,51], pharmacokinetics and dimensions of MB [64–66], molecular weight or size of the 
delivered agents [29,67], the biological properties of the microvasculature, etc. Despite several in vivo 
experiments having been carried out under different conditions [50,68–70], there is still a lack of a 
comprehensive mathematical model with which to describe the dependence of the permeability 
enhancement on the aforementioned key factors. Therefore, parameter studies were not performed 
in this pilot study to understand their effects. Extensive experimental data are required to establish a 
model for optimisation of this treatment design. 
The treatment efficacy was found to be non-linearly correlated to the drug release rate. On one 
hand, the fast release enabled more drug to be released, achieving a high concentration in a short 
period of time. However, as shown in Table 1, the elimination and plasma clearance rate of free drug 
was orders of magnitude higher than when using liposomes. Consequently, the drug concentration 
reduced quickly to zero, leading to a low drug exposure over time in the tumour. On the other hand, 
the slow release could theoretically lead to a sustainable supply of free drug. It is still important to 
note that liposomes are continuously washed out by plasma clearance. As a result, drugs are highly 
likely to be cleared out of the body before even being released. Therefore, the release rate needs to be 
optimised to maximise anticancer effectiveness by maintaining a balance among drug release, 
transvascular exchange and elimination. A general liposome with the same release rate in IVS and 
ECS was applied in this study. However, this rate could be different depending on the intratumoural 
environment. For instance, drug release from pH-sensitive liposomes could be much quicker in 
tumour ECS than in blood, as acidity of the environments differs [71]. Thermosensitive liposomes are 
designed to be stable at body temperature, while a burst drug release can be achieved when the 
environmental temperature is above the pre-designed threshold [56,59]. Subsequent studies could 
therefore focus on the relationship between release rate and intratumoural environment in order to 
provide suggestions for improvement of the liposome properties. 
The BBB can be permeabilised using FUS in a non-invasive, reversible manner. With the 
guidance of transcranial MR imaging, the targeting accuracy of FUS can be further improved to 
achieve localised treatment [72]. In practice, ultrasound contrast agents in the form of microbubbles 
are intravenously administrated as a first step. This is followed by the projection of FUS into the 
designed region of the brain. Triggered by the ultrasound, the microbubbles become activated to 
produce a range of chemical, mechanical and thermal effects that can transiently disrupt the tight 
junctions of the endothelial cells on the blood vessel wall [73]. The ability of this BBBD to improve 
drug delivery has been reported in terms of animal experiments in literature [74]. Moreover, there 
has been no significant brain tissue damage found in clinical trials [75], demonstrating the accuracy 
and safety of this combination drug-delivery strategy. 
A multiphysics model was employed in this study to examine the effects of FUS- and MB-
induced BBBD on drug transport in chemotherapy. The IFV was predicted as 0.43 and 0.13 μm/s in 
the brain tumour and its surrounding tissue, respectively, values which are both well within the 
range of 0.1 to 1.0 μm/s measured previously in in vivo experiments [33,43]. As compared to 
liposome-mediated delivery without BBBD, the doxorubicin concentration at 2 h after sonication was 
2.08 times higher when FUS and MB were applied. This finding agrees with the animal experiments 
where FUS-MB-induced improvement was measured in the range of 1.51- to 2.65-fold [76]. Besides 
the BBBD model based on semi-empirical formulas from experiments [21,32], the drug transport 
model has been widely applied in previous numerical studies on drug delivery and validated by 
comparison with experimental results. The IFP and IFV were calculated as 1500 Pa [77] and 0.17 μm/s 
[12], respectively, which were within the experimental ranges of 586 to 4200 Pa [78] and 0.13 to 0.20 
μm/s [79]. Model-predicted drug transport profiles were well fit to the measurements reported from 
ex vivo experiments, with the coefficient of multiple determination reaching 0.83 [80]. Although 
comparisons to animal experiments remain qualitative for small molecular drugs [81,82], the 
prediction accuracy can be largely improved for the drug vehicles in nanoscale [83]. Therefore, since 
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this study was focused on drug transport rather than model development, the work of model 
validation was not duplicated here. 
The present study offers some new insight into the enhancement of liposome-mediated drug 
delivery into brain tumour via FUS and MB; however, there were several assumptions involved. (I) 
FUS sonication is usually performed using an ultrasound transducer with its focus point swapping 
across the brain tumour, so the BBBD could be non-uniform across the entire brain. As the 
optimisation of FUS trajectory for achieving homogeneous BBBD was beyond the scope of this study, 
the enhancement of drug transvascular permeability was assumed to be perfectly restricted within 
the brain tumour and uniformly distributed. (II) Liposomes are able to cross the cell membrane by 
endocytosis and then release the drug intracellularly [84]. However, as with the liposomes used in 
study, polyethylene glycol (PEG) is usually applied to modify the liposome surface in order to 
achieve extensive survival time in blood circulation. This ligand effectively inhibits endocytosis by 
forming a steric barrier to prevent liposome–cell membrane interaction [85,86]. Therefore, 
endocytosis was not considered here, and liposomes were assumed to be impermeable to cell 
membrane. (III) The spatial distribution of microvasculature can be highly heterogeneous in large 
tumours. This heterogeneity can affect local drug supply, and thereby influence drug transport and 
accumulation. The microvasculature was assumed to be homogeneously distributed in the brain 
tumour, as there was a lack of relevant information that could be obtained from available medical 
images. This assumption could be relaxed by using dynamic, contrast-enhanced MR images [81], 
from which vasculature density can be predicted based on the time course of signal intensity at each 
image pixel. 
It is of note that the mathematical model was developed to cover the key biophysical and 
physicochemical processes in drug delivery. The applied model parameters refer to the 
representative values that were extracted from the literature. The model predictions could be used 
for qualitative comparisons to examine the effects of specified processes, so as to provide guidance 
for the optimisation of treatment regimens and liposome properties. The modelling accuracy could 
be improved by employing patient-specific information and developing mathematical descriptions 
for particular processes in drug delivery. These would require extensive support from medical 
imaging and in vivo experiments, respectively. 
5. Conclusions 
Drug transport in the liposome-mediated delivery coupled with FUS- and MB-induced BBBD 
was investigated by means of numerical simulation in this study. A 3D brain tumour model 
reconstructed from MR images was applied with the aim of capturing the realistic geometrical 
characteristics of the lesion. Although doxorubicin could enter the tumour ECS when the BBB was 
disrupted by FUS and MB, modelling predictions demonstrated that the use of liposomes could 
further improve the treatment efficacy under the same delivery conditions. This improvement mainly 
relied on the enhanced transvascular permeability of free doxorubicin and the sustainable drug 
supply from the long-circulating liposomes when burst FUS sonication was applied. The anticancer 
effectiveness of this treatment could be improved by extending the sonication time window, which 
largely improved the accumulation of both liposomal and free drug in tumour ECS. The release rate 
needs to be optimised to achieve an acceptable trade-off among drug release, transvascular exchange 
and elimination. The BBBD is recommended to be carried out simultaneously with the bolus injection 
of liposomes, as late BBBD reduces the anticancer efficacy but retains a similar risk of cardiotoxicity. 
Results obtained from this study could provide suggestions for the future optimisation of FUS-MB–
liposome-mediated drug delivery. 
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